Kezar Life Sciences (NASDAQ:KZR) Posts Quarterly Earnings Results, Misses Estimates By $0.60 EPS

Kezar Life Sciences (NASDAQ:KZR) announced its earnings results on Friday. The company reported ($1.99) EPS for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.60), FiscalAI reports.

Kezar Life Sciences Stock Performance

Shares of NASDAQ KZR traded down $0.15 during trading hours on Friday, reaching $6.20. The stock had a trading volume of 27,253 shares, compared to its average volume of 37,123. The company has a current ratio of 7.07, a quick ratio of 7.06 and a debt-to-equity ratio of 0.02. Kezar Life Sciences has a fifty-two week low of $3.53 and a fifty-two week high of $7.45. The firm has a 50-day moving average of $6.52 and a 200-day moving average of $5.87. The firm has a market cap of $45.40 million, a price-to-earnings ratio of -0.73 and a beta of 0.53.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kezar Life Sciences in a research report on Monday, December 22nd. Four analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Kezar Life Sciences currently has an average rating of “Reduce” and an average price target of $6.00.

Hedge Funds Weigh In On Kezar Life Sciences

Institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC purchased a new position in shares of Kezar Life Sciences during the 4th quarter worth approximately $1,741,000. Affinity Asset Advisors LLC acquired a new stake in Kezar Life Sciences during the 4th quarter valued at $1,441,000. Aldebaran Capital LLC acquired a new stake in Kezar Life Sciences during the 4th quarter valued at $507,000. Vazirani Asset Management LLC purchased a new position in Kezar Life Sciences during the fourth quarter worth $305,000. Finally, Woodline Partners LP acquired a new position in shares of Kezar Life Sciences in the first quarter worth $125,000. 67.90% of the stock is owned by institutional investors and hedge funds.

Kezar Life Sciences Company Profile

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.